Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated)

Description

Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated) are derived from the peripheral blood of newly diagnosed and untreated multiple myeloma patients. They are separated by gradient centrifugation technology (such as Ficoll density gradient method) to obtain a mixed cell population rich in lymphocytes (T/B cells, NK cells), monocytes and dendritic cells. Morphologically, the cells are round and mononuclear, grow in suspension, and have weak adhesion ability. Clonal B cells overexpress monoclonal immunoglobulins; increased myeloid-derived suppressor cells (MDSCs) markers; T cells show inhibited function via arginase 1 and IDO pathways.Functionally, they contain immune surveillance and regulatory components, but they are abnormal due to the disease state: B cells proliferate clonally and secrete monoclonal immunoglobulins, the proportion of myeloid-derived suppressor cells (MDSCs) increases, and T cell function is inhibited through pathways such as arginase 1 and IDO, promoting tumor immune escape.

Application

• Multiple myeloma is a plasma cell malignancy characterized by monoclonal plasma cell infiltration in the bone marrow, elevated serum M protein and organ damage (such as bone disease, renal failure). These cells are important models for studying the pathogenesis, drug resistance and development of targeted therapies (such as proteasome inhibitors and immunomodulatory drugs) of multiple myeloma, and are particularly suitable for exploring the biological behavior of early diseases and screening targets for immunotherapy (such as CAR-T).